期刊文献+

雷洛昔芬中间体4-甲氧基-α-[(3-甲氧基苯基)硫代]苯乙酮含量的反相高效液相色谱测定 被引量:1

Determination of Content of Raloxifen Intermediate 4-Methoxy-α-[(3-methoxyphenyl)thio]Acetophenone by R-HPLC
下载PDF
导出
摘要 采用反相高效液相色谱法,以v(甲醇)v∶(水)=802∶0作为流动相,用C18柱和二极管阵列检测器(DAD,282nm),测定4-甲氧基--α[(3-甲氧基苯基)硫代]苯乙酮的含量。结果表明,4-甲氧基--α[(3-甲氧基苯基)硫代]苯乙酮在0.02~0.90μg内呈良好的线性关系,r=0.99999。该方法灵敏、快速、准确,可用于4-甲氧基--α[(3-甲氧基苯基)硫代]苯乙酮含量的测定。 A quantitative analytical method of 4-Methoxy-α-[(3-Methoxyphenyl)thio] acetophenone by R- HPLC was described, using υ (methanol) : υ (water) = 80 : 20 as mobile phase, using Kromasil C18 column at DAD detector(282 nm). Result showed that 4-methoxy-α-[ (3-methoxyphenyl)thio] acetophenone was linear (r = 0.999 99)and had a good linear correlation in the range of 0.02~0.90μg, This suggested that the method was proved to be sensitive, fast and accurate, and could be used for determining the content of 4-methoxy-α-[ (3-methoxyphenyl)thio] acetophenone.
出处 《精细化工中间体》 CAS 2006年第6期65-67,共3页 Fine Chemical Intermediates
基金 贵州省省长基金项目(2005374)
关键词 4-甲氧基-α-[(3-甲氧基苯基)硫代]苯乙酮 检测 高效液相色谱 4-methoxy-α- [ (3-methoxyphenyl)thio ] acetophenone determination HPLC
  • 相关文献

参考文献5

二级参考文献18

  • 1[13](a)Eur Pat Appl EP 6171030 (CL C07D333/56), 28 Sep 1994. (b)Int pat Appl Ep707,852 (CL A61K31/40) 21 Apr 1996.
  • 2[14]Dodge JA, Lugar CW, Cho S, et al. Evaluation of the major metablites of raloxifene as modulator of tissue selectivity. J Steroid Biochem Molec Biol, 1997, 61:97
  • 3[15]Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci, 1997, 94(25):14105
  • 4[16]Yang NN, Venugopala M, Hardikar S, et al. Identification of estrogen response element activated by metablites of 17-β-estradiol and raloxifene. Science, 1996, 273(753):1222
  • 5[17]Bryant HU, Dere UH. SERMs, Multiple pathway for ER responses. Proc Soc Exp Biol Med, 1998, 217(1):45
  • 6[1]Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogens. Structure-activity studies in a series of 3-Kroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl) benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]menthanone hydrochloride (LY156758), a remarkablely effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem, 1984, 27:1057
  • 7[2]Thompson EW, Reich R, Shima TB, et al. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res, 1988, 48:6764
  • 8[3]Anzano MA, Peer CW, Smith JM, et al. Chemprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinic acid. J Nat'l Cancer Inst, 1996, 88(2):123
  • 9[4]Zuckerman SH, Bryan N. Inhibition of LDL oxidationa and myeloperoxidase dependent tyrosl radical formation by the selective estrogen receptor modulator raloxifene (LY 139481 HCL). Atherosclerosis, 1996, 126:65
  • 10[5]Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY 139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest, 1994, 93:63

共引文献41

同被引文献15

  • 1金义翠.高效液相色谱法测定盐酸雷洛昔芬原料药有关物质[J].化学工业与工程技术,2004,25(5):56-57. 被引量:4
  • 2王金科.雷洛昔芬[J].中国新药杂志,2000,9(2):124.
  • 3Gizzo S, Saccardi C, Patrelli TS, et al. Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, andcontraindications [J]. Obstet Gynecol Surv, 2013, 68 ( 6 ) : 467-481.
  • 4Teeter JS, MeyerhoffRD. Environmental fate and chemistry of raloxifene hydrochloride [J]. Environ Toxicol Chem, 2002, 21 (4) : 729-736.
  • 5Lippuner K, Buchard PA, De Geyter C, et al. Recom- mendations for raloxifene use in daily clinical practice in the Swiss setting [J]. Eur Spine J, 2012, 21 ( 12 ) : 2407-2417.
  • 6Tran TH, Poudel BK, Marasini N, et al. Development of raloxifene-solid dispersion with improved oral bio- availability via spray-drying technique [J]. Arch Pharm Res, 2013, 36 (1) : 86-93.
  • 7Tran TH, Ramasamy T, Cho H J, et al. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability [J]. J Nanosci Nanotechnol, 2014, 14 (7) : 4820-4831.
  • 8Rahman MA, Harwansh R, Mirza MA, et al. Oral lipid based drug delivery system ( LBDDS ) : formulation, characterization and application: a review [J]. Curr Drug Deliv, 2011, 8 (4) : 330-345.
  • 9金倩倩,陈修克,金滔,诸佳珍,尚小广,刘敏臣,李范珠.大豆异黄酮对盐酸雷洛昔芬在大鼠体内的药动学研究[J].中药药理与临床,2011,27(4):40-43. 被引量:5
  • 10黄涛,刘世清,张弩,陈庆,张春,廖琦,赵奇.雷洛昔芬治疗绝经后妇女骨质疏松症的系统评价[J].中国骨质疏松杂志,2013,19(4):391-397. 被引量:20

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部